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Background and aims: Breast cancer is the most common cancer in women and the second leading cause
of cancer-related deaths in this population. Breast cancer related deaths have declined due to screening
and adjuvant therapies, yet a driving clinical need exists to better understand the cause of the deadliest
aspect of breast cancer, metastatic disease. Breast cancer metastasizes to several distant organs, the liver
being the third most common site. To date, very few murine models of hepatic breast cancer exist.
Methods: In this study, a novel murine model of liver breast cancer using the MDA-MB-231 cell line is
introduced as an experimental (preclinical) model.
Results: Histological typing revealed consistent hepatic breast cancer tumor foci. Common features of the
murine model were vascular invasion, lung metastasis and peritoneal seeding.
Conclusions: The novel murine model of hepatic breast cancer established in this study provides a tool to
be used to investigate mechanisms of hepatic metastasis and to test potential therapeutic interventions.
& 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Breast cancer is the most common cancer in women and the
second leading cause of cancer-related deaths in this population. It
is estimated that there will be 231,840 new cases of breast cancer
and 40,290 breast cancer related deaths in women in 2015 [1]. The
survival rate for patients diagnosed with breast cancer is a func-
tion of a variety of factors, the most important being metastasis. In
fact, the survival rate for patients diagnosed with metastatic breast
cancer to distant organs falls from 99% to 25% when compared to
primary site-only cases [1]. Although 61% of breast cancers are
localized, 10–15% of patients develop metastasis to distant organs
[1,2]. Predicting the risk of metastasis is often difﬁcult due to a lack
of biological markers and the heterogeneous nature of breast
cancer [2]. Histological typing does not provide tremendousr B.V. This is an open access article
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A.predictive value for metastasis, yet invasive ductal carcinoma is
the most common invasive breast carcinoma and has one of the
lowest survival rates [2]. At a molecular level, HER2-enriched and
triple-negative (estrogen receptor negative, progesterone receptor
negative and HER2 negative) tumors are associated with a higher
rate of liver metastases [3]. The fact that metastasis does not re-
spond well to traditional management techniques of surgery, ra-
diation and chemotherapy is a key motivator to developing better
research models [2,4].
Murine models are a useful tool for researchers and oncologists
in characterizing and understanding the spread of breast cancer. A
summary of these models is presented in Table 1. Unto now, a
model of primarily hepatic metastasis is lacking. In this study, we
report the development of a novel murine model of hepatic breast
cancer using the breast cancer cell line MDA-MB-231, a triple-
negative adenocarcinoma cell line derived from a 51-year-old
Caucasian female [5].2. Materials and methods
2.1. Preconditioning with Ad:uPA
Cesium chloride banded and plaque assay titered Ad: uPA was
diluted to 1.25109 plaque forming units (pfu)/100 mL in sterileunder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Literature review of murine models of hepatic breast cancer. The table states the cell lines for various murine models of breast cancer hepatic metastasis as well as the
purpose of each study.
Cell Line Mouse Inoculation site Liver met? Other met? Study purpose Reference
MDA-MB-435 Female nude Mammary fat pad Yes Yes Use of surgical orthotopic implantation [7]
MDA-MB-435 Female athymic NU/NU Right second mammary gland Yes Yes Optical imaging [8]
4T1 Female BALB/c Mammary fat pad Yes Yes Effect of bisphosphonate [9]
4T1 Female BALB/c Mammary fat pad Yes Yes Effect of factor 4 [10]
4T1 Female BALB/c Mammary fat pad Yes Yes Use of dabigatran [11]
4T1 Female BALB/c Mammary fat pad Yes Yes Effect of R428 [12]
4T1 BALB/cfC3H Mammary fat pad Yes Yes Imaging [13]
4T1/luc BALB/c Mammary fat pad Yes Yes Effect of zoledronic acid [14]
MDA-MB-231 Female NCr nu/nu Mammary fat pad Yes Yes Effect of pro-matrix metalloproteinase-2 [15]
MDA-MB-231 Female athymic nude Mammary fat pad Yes Yes Effect of GLV-1h153 in TNBC [16]
MDA-MB-231 BALB/cAnN.CG-Foxn1 nu/
CrINar
Tail vein Yes No Effect of VP1 [17]
MDA-MB-231 Mammary pat Yes Yes Effect of PEDF [18]
MDA-MB-231 Female nude Mammary fat pad Yes Yes Effect of CH50 [19]
MDA-MB-231/
luc
Female Rag2-/-II2rg-/- Mammary fat pad Yes Yes Effect of phenytoin on TNBC [20]
4TLM BALB-c Right upper mammary gland Yes Yes Multi metastatic model [21]
4THM BALB-c Second right chest mammary pad Yes Yes Effect of semapimod [22]
R. Rikhi et al. / Biochemistry and Biophysics Reports 8 (2016) 1–520.9% saline and ﬁltered using an Acrodisc syringe ﬁlter with
0.45 mM HT Tuffryn membrane. Each mouse was anesthetized
using isoﬂurane and dosed via retro-orbital vein injection with
1.25109 pfu per 25 g of body weight.2.2. Transplant with human MDA-MB-231 cells
Cryopreserved human MDA-MB-231 cells (Xentech, France)
were thawed and expanded in Advanced DMEM with 10% fetal
bovine serum and antibiotics. After expansion, the cells were de-
tached from the tissue culture plate by treatment with TryPLE,
collected, and centrifuged at 150 g for 10 min at 4 °C. The MDA-
MB-231 cells were resuspended in HCM (catalog# CC-3198, Lonza,
Basel, Switzerland) to a concentration of 1–2106 cell/mL and
diluted 1:1 in 0.4% trypan blue; the cell number and viability were
determined using a hemocytometer. MDA-MB-231 cells were
centrifuged again at 150 g for 10 min at 4 °C and reconstituted in
HCM (Lonza) at 10106 cells/mL. To counteract rapid vascular
clearing and allow adequate time for liver engraftment, the MDA-
MB-23 cells were then mixed 1:1 with Matrigel phenol red free
(cat#356237, BD Biosciences, San Jose, CA); this generated a 100 mL
transplant solution. The mixture was kept on ice to prevent the
Matrigel phenol red free from solidifying.
All animal studies were done with approval of the IACUC for
Yecuris, Inc. FRG™ KO/NOD mice were anesthetized using iso-
ﬂurane. Hair was removed from the lateral region and mid-line of
each animal using Nairs hair removal cream, Then the 100 mL of
transplant solution was delivered through the dermal layer into
the frontal lobe of the liver 22–24 h after pretreatment with Ad:
uPA. The mice were observed each day post-transplant and were
provided water and food ad libitum. The transplanted mice were
placed on the standard Nitisinone cycling for all xenografted mice.2.3. Human AFP ELISA
Human alpha-1 fetoprotein (AFP) ELISA kit (cat#ab108838) was
obtained from Abcam (Cambridge, MA). Sera samples were col-
lected at four weeks post-transplantation and stored at 80 °C
until assayed. The human AFP levels from each mouse were as-
sayed using 50 mL of sample at a 1:5, 1:20 or 1:100 dilution of sera
according to the manufacturer's protocol.2.4. Immunostaining
Immunohistochemical staining was performed on formalin-ﬁxed,
parafﬁn-embedded tissue sections. Four micron sections were pre-
pared on charged slides. Staining was performed on Ventana XT
automated instruments (Ventana, Tucson, AZ) with ultra-view
polymer-based DAB detection system. Clone designations, working
dilutions, and sources for the commercially available antibodies were
as follows: AFP (Clone A0008, dilution 1:3000, Dako, Carpinteria, CA),
Hep Par 1 (Clone M7158, dilution, 1:250, Dako), Glypican 3 (Clone
790-4564, predilute, Ventana, Tucson, AZ), Her 2-neu (Clone 790-
2991, predilute, Ventana), p53 (Clone 790-2912, predilute, Ventana),
Ki-57 (Clone 790-4286, predilute, Ventana) Sections were counter-
stained with hematoxylin. Appropriate positive and negative controls
were present in every case. Negative controls were performed by
replacing the primary antibody with normal mouse serum. Final
interpretation of the staining results was performed by a surgical
pathologist using light microscopy.3. Results
To create a murine model of hepatic breast cancer, we pre-
formed direct injection of MDA-MB-231 cells into the frontal lobe
of the liver (Fig. 1A) of mice previously shown to have a capacity to
be repopulated with primary human hepatocytes. This FRG™ KO [
Fah(-/-) R ag2(-/-)Il2r g (-/-)]) on the NOD mouse strain has been
previously described [6]. In this model, however, co-injection of
primary human hepatocytes offered no additional beneﬁt to en-
graftment, but only increased the degree of necrosis (data not
shown). Therefore analysis was restricted to FRG™ KO/NOD mice
injected with MDA-MB-231 tumor cells only. Histological typing
revealed exclusively breast cancer cells (and not murine hepatic
tumors). Characteristic human breast cancer liver metastases are
shown in Fig. 1B and Fig. 1C. The murine model approximated this
histology (Fig 1D-1F). Common features of the model were vas-
cular invasion (Fig. 1G), lung metastasis (Fig. 1H) and peritoneal
seeding (not shown). There was no splenic disease seen in the
model. The immunostains for intrinsic liver cancer markers AFP,
Hep Par 1 and GPC3 were all negative (Fig. 2). The immunostain
for Her-2 neu were negative, and immunostain for p53 was posi-
tive in 80% of tumor cells and the Ki-67 proliferation index was
60% (Fig. 2). An ELISAwas done in order to measure serum AFP, but
the level was below the limit of detection.
Fig. 1. Murine model of hepatic breast cancer (A) Diagram of murine engraftment. (B, C) Photomicrograph of liver metastasis in a human patient. (D) Murine tumor of almost
exclusively an undifferentiated cell component. (E, F) Additional histological features of the murine model. (G) Vascular invasion was a prominent (depicted with red arrows),
and (H) lung metastasis was a consistent feature. Peritoneal seeding was common but no intrasplenic disease was seen (data now shown).
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Fig. 2. Immunostains for intrinsic hepatic and breast cancer markers (A) Intrinsic liver marker AFP. Serum AFP by ELISA was below the limit of detection (data not shown).
(B) Liver marker Glypican-3. (C) Liver marker Hep Par 1. (D) Cancer marker HER2/Neu. (E) Cancer marker P53. (F) Cancer marker Ki-67 (nuclear).
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A strong clinical need exists to better understand breast cancer
metastasis. The novel murine model of hepatic breast cancer es-
tablished in this study provides a tool to be used to investigate
mechanisms of hepatic metastasis and potential therapeutic in-
terventions. Characteristics of this murine model are consistent
with clinical features of breast cancer metastasis, such as vascular
invasion and metastasis to the lung (the second most common
organ affected by breast cancer metastasis) [2]. Furthermore, tu-
mors in these FRG™ KO/NOD mice cannot be attributed to strain
background, as the tumor markers in this model were not con-
sistent with primary hepatic tumors. While a limitation of this
model was that it was not generated with a HER2þ cell line, fu-
ture studies may include this biological feature. However, the tu-
mor samples were positive for well-established breast cancer cell
markers p53 and Ki-67. It is also important to note that there wasno control for the FAH phenotype in this experiment. Future stu-
dies will investigate the necessity and level of beneﬁt of the FAH
phenotype in engraftment. In summary, however, the procedure
reported here represents a reproducible way to generate a hepatic
breast cancer preclinical model to understand tumor-micro-
environment interactions and to test preclinical therapeutic
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